Clinical Trial Update: Evaluating Sublingual Dexmedetomidine For Moderate To Severe Agitation In Inpatients With Schizophrenia Or Bipolar Disorder [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating sublingual dexmedetomidine for moderate to severe agitation in inpatients with schizophrenia or bipolar disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• Dexmedetomidine (Dexmedetomidine)

Snippet

Sponsor: Temple University | Conditions: Schizophrenia Agitation, Schizo Affective Disorder | Phase 4 | Status: UNKNOWN